Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials
BackgroundDespite advances in targeted therapies and immune checkpoint inhibitors (ICIs), the prognosis for advanced non-small cell lung cancer (NSCLC) remains poor. Bispecific antibodies (BsAbs) represent an emerging class of dual-target immunotherapi…